

Transcytosis-associated protein (TAP)/p115 is a general fusion factor required for binding of vesicles to acceptor membranes

MARGARIDA BARROSO, DAVID S. NELSON, AND ELIZABETH SZTUL*

Department of Molecular Biology, Princeton University, Princeton, NJ 08544

Communicated by James E. Rothman, Memorial Sloan-Kettering Cancer Center, New York, NY, September 8, 1994 (received for review August 25, 1994)

ABSTRACT Transcytosis-associated protein (TAP) is found on transcytotic vesicles (TCVs) and is required for their fusion with the target membrane. We developed a cell-free assay capable of differentiating targeting/binding of TCVs to membrane from later fusion events. We found that TAP mediates stable association of TCVs with the target membrane. The sequence of rat liver TAP (959-amino acid open reading frame) encodes a protein that contains (i) an N-terminal region (amino acids 1–649), (ii) an internal region with several coiled-coil stretches (amino acids 650–930), and (iii) a C-terminal acidic region (amino acids 931–959). Comparisons between TAP and other sequences indicate that TAP is identical to p115, a protein involved in *cis* to medial Golgi transport, and homologous to Uso1p, a yeast protein involved in endoplasmic reticulum to Golgi transport. Our findings suggest that TAP/p115/Usop1 is a general factor acting within the secretory and endocytic pathways to bind transport vesicles prior to membrane fusion.

Vesicular transport (transcytosis) of proteins from the basolateral to apical plasma membrane (PM) of polarized epithelial cells has been extensively studied (1, 2). We have designed a cell-free assay reconstituting the last step of transcytosis, the fusion of transcytotic vesicles (TCVs) with the apical PM (3–6), and have identified two proteins, *N*-ethylmaleimide-sensitive fusion protein (NSF) and transcytosis-associated protein (TAP), which are required for fusion (3, 7). We now further analyze TAP's role by establishing a modified *in vitro* assay that differentiates between the targeting/binding stage and subsequent steps of the fusion reaction. We show that TAP is required for the binding of TCVs to the PM.

We have cloned and sequenced TAP.[†] TAP's sequence is identical to that of p115 (8), a protein originally shown to be required for *cis* to medial Golgi transport (9) and subsequently for an uncoupled reaction measuring exclusively intra-Golgi fusion (10). TAP also shares highly conserved regions with a yeast protein Uso1p, which among other pleiotropic effects has been implicated in endoplasmic reticulum (ER) to Golgi traffic (11).

MATERIALS AND METHODS

SDS/PAGE and Immunoblotting. Samples were processed for SDS/PAGE and immunoblotting as described (3, 12). Immunoblots were processed by chemiluminescence and filters were exposed to x-ray film.

Cell-Free Assay. *In vivo* radiolabeled donor fractions and unlabeled target fractions and cytosol were prepared from rat livers as described (3). Fusion assays and analysis of polymeric IgA receptor (pIgA-R) were performed as described (3). In some experiments, reaction mixtures were centrifuged, and supernatant and pellets were separated. For the immunodeple-

tion experiments, anti-TAP antibodies were purified from culture supernatants using protein G-Sepharose (Pharmacia) and coupled to Affi-Gel 10 (Bio-Rad) support matrix. TAP-immunodepleted cytosol was prepared by incubating cytosol with 4G2 monoclonal antibodies (mAbs) covalently bound to the Affi-Gel support at 4°C.

TAP Purification. Rat livers were homogenized in 25 mM Tris-HCl, pH 7.4/250 mM sucrose/150 mM KCl/1 mM dithiothreitol. The homogenate was centrifuged, the supernatant was collected, and ammonium sulfate was added to a concentration of 40%. The pellets were recovered, resuspended in TD (25 mM Tris-HCl/1 mM dithiothreitol) and diluted to a conductivity equal to TD containing 150 mM KCl (150KTD). This material was loaded onto a DEAE-Sepharose (Pharmacia) column equilibrated with 150KTD. The column was eluted with a gradient of 150–600KTD. Fractions were analyzed by immunoblotting with polyclonal anti-TAP antibody. A concentrated pool was loaded onto a Superose 6 (Pharmacia) column equilibrated with 150KTD. TAP-containing fractions were pooled and loaded onto a Mono Q (Pharmacia) column equilibrated with 150KTD. The column was eluted with a gradient of 150–600KTD.

mAbs. Mono Q fractions were used as antigen to generate antibodies in mice (13). Screening of hybridomas was performed by immunoblotting. Two cell lines secreting anti-TAP antibodies were used in this study.

Cloning and Sequencing. We used degenerate oligonucleotide primers corresponding to amino acid residues QHD-NIVTH (amino acids 647–654) and TQQASQIQ (amino acids 688–695) to amplify a cDNA fragment from reverse-transcribed total liver RNA (SuperScript kit; GIBCO/BRL). The resulting PCR fragment was cloned and sequenced and was 84% homologous to a human partial cDNA sequence (GenBank accession no. Z24991). The fragment was used to screen an oligo(dT)-primed λ ZAP II cDNA library from a rat liver cell line. A 5'-terminal restriction fragment of a partial cDNA clone was used to screen a random-primed rat liver cDNA library in pUEX. A single clone (\approx 1.6 kb) was isolated that contained the 5' end of the TAP coding sequence. Standard procedures were used for cloning and sequencing (14).

RESULTS AND DISCUSSION

Anti-TAP mAbs. Previously, we demonstrated that cytosol immunodepleted of TAP failed to support fusion of TCVs with apical PM (3), but these experiments used a polyspecific polyclonal antibody raised against purified TCVs (15). To

Abbreviations: PM, plasma membrane; TCV, transcytotic vesicle; NSF, *N*-ethylmaleimide-sensitive fusion protein; TAP, transcytosis-associated protein; ER, endoplasmic reticulum; pIgA-R, polymeric IgA receptor; mAb, monoclonal antibody; ORF, open reading frame; SNAP, soluble NSF attachment protein; SNARE, SNAP receptor.

*To whom reprint requests should be addressed.

[†]The sequence reported in this paper has been deposited in the GenBank data base (accession no. U15589).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

unequivocally show that TAP is required for transcytotic fusion, we used mAb immunodepletion to prepare TAP-free cytosol. Such cytosol was then used in the cell-free assay to determine whether it could support fusion and, if not, whether addition of purified TAP could reconstitute fusion.

To test the mAbs, cytosolic proteins were immunoblotted with either the mAbs or the polyclonal anti-TAP antibody. As shown in Fig. 1A, for the 5D6 mAb, only TAP was detected (lane 2), while the polyclonal anti-TAP antibody reacted with TAP but also detected other minor proteins (lane 3). To ensure that the mAbs recognize the same protein as the polyclonal anti-TAP antibody, cytosol was subjected to immunoprecipitation with 4G2 and 5D6 mAbs or without antibodies and then immunoblotted with the polyclonal anti-TAP antibody. As shown in Fig. 1B, TAP was present in the +mAb immunoprecipitates (lanes 1 and 4) but was absent from the -mAb immunoprecipitate (lane 3). These results indicate that the mAbs immunoprecipitate TAP. The 4G2 mAb was used to immunopurify TAP from cytosol (Fig. 1C).

TAP Is Required for Transcytotic Fusion. 4G2 mAb was used to immunodeplete cytosol (removing >95% of TAP), which was then tested in the transcytotic cell-free assay. The donor fraction was prepared from *in vivo* radiolabeled rats and contains TCVs that carry radiolabeled 120-kDa pIgA-R. The target fraction was prepared from unlabeled rats and contains an inside-out apical PM that has an exoprotease capable of cleaving pIgA-R to an ~90-kDa fragment. When donor and target fractions were mixed with cytosol and an ATP-regenerating system and incubated at 37°C, fusion occurred as measured by the cleavage of 120-kDa pIgA-R to the ~90-kDa fragment (Fig. 2, lane 1). Under control conditions, 50–80% fusion is routinely observed. A similar result (lane 4) was observed when mock-depleted cytosol was used. However, no fusion was observed (lane 7) when TAP-depleted cytosol was tested. Addition of purified TAP (lane 8) reversed the inhibition to the same extent as addition of untreated cytosol (lane 9). Addition of purified TAP or untreated cytosol to reaction mixtures containing untreated cytosol (lanes 2 and 3) or to reaction mixtures containing mock-depleted cytosol (lanes 5 and 6) did not increase fusion efficiency.

Dissection of the Transcytotic Assay. To address the role of TAP at a more refined level, the cell-free assay was dissected into distinct stages by changing the end-point readout; instead of measuring fusion, we assayed the association of TCVs with the target PM. We developed a velocity centrifugation protocol (based on the large difference in size between the donor TCVs and the target PM), which can separate free TCVs from




FIG. 1. Characterization of anti-TAP mAbs. (A) Rat liver cytosol was processed by SDS/PAGE and stained with Coomassie blue (lane 1) or immunoblotted with 5D6 mAb (lane 2) or with polyclonal anti-TAP antibody (lane 3). (B) Cytosol was immunoprecipitated with 4G2 and 5D6 mAbs or without antibody. Immunoprecipitated proteins were immunoblotted with the polyclonal anti-TAP antibody. Cytosol was included to indicate position of TAP. (C) 4G2 mAb was used to immunopurify TAP from cytosol. A Coomassie blue-stained SDS/polyacrylamide gel of purified material is shown.




FIG. 2. TAP is required for transcytotic fusion. Fusion reaction mixture containing untreated cytosol, mock-depleted cytosol, or TAP-depleted cytosol were incubated at 37°C for 60 min (lanes 1, 4, and 7) or were supplemented with purified TAP (lanes 2, 5, and 8) or with untreated cytosol (lanes 3, 6, and 9) prior to incubation at 37°C. pIgA-R was immunoprecipitated and analyzed by SDS/PAGE and fluorography.

the target PM. The donor or the target fraction was incubated in a complete reaction mixture at 37°C for 60 min and then centrifuged. The extent of sedimentation of the donor fraction in the absence of the fusing partner was analyzed by examining the resulting pellet and supernatant for the content of the 120-kDa form of pIgA-R. Pelletability of the target fraction in the absence of donor was assayed by examining the pellet and supernatant fractions for content of the apical PM protein dipeptidyl-peptidase IV. As shown in Fig. 3A (untreated bars), the centrifugation results in minimal (~10%) pelleting of TCVs, but as shown in Fig. 3B (untreated bars), it results in extensive (~65%) sedimentation of target PM.

Donor or target fractions were supplemented with reaction mixtures containing TAP-depleted cytosol or an ATP-depleting system at 37°C for 60 min and centrifuged. As shown




FIG. 3. Establishing the targeting/binding assay. Donor or target fraction was incubated in a reaction mixture containing untreated cytosol (untreated bars), TAP-depleted cytosol (TAP-depleted bars), or untreated cytosol and ATP-depleting system (ATP-depleted bars). Reaction mixtures were incubated at 37°C for 60 min and then separated by centrifugation. (A) Amount of pelleted and nonpelleted donor TCVs was assayed by immunoblotting with anti-pIgA-R antibodies. (B) Pelleting characteristics of the target PM was determined by immunoblots with anti-dipeptidyl-peptidase IV antibodies.

in Fig. 3A (TAP-depleted and ATP-depleted bars), there was no change in the sedimentation characteristics of TCVs. Similarly, as shown in Fig. 3B (TAP-depleted and ATP-depleted bars), the pelletability of the target apical PM under such conditions is similar to that seen in the control reaction.

TAP Is Required for Binding of TCVs to Target Membrane.

To examine the stage at which TAP is required for transcytotic fusion, we analyzed the centrifugation behavior of three fusion reaction mixtures: (i) control reaction mixture (containing donor and acceptor, untreated cytosol, and an ATP-regenerating system); (ii) reaction mixture containing TAP-depleted cytosol; and (iii) reaction mixture containing an ATP-depleting system. As shown in Fig. 4A, fusion occurs in the control (lane 1) reaction mixture but is inhibited in the TAP-depleted (lane 2) and ATP-depleted (lane 3) reaction mixtures. An aliquot of each reaction mixture was subjected to centrifugation and the resulting supernatant and pellet fractions were analyzed by SDS/PAGE and fluorography to determine their content of radiolabeled pIgA-R. As shown in Fig. 4B (lanes 1 and 2), $\approx 82\%$ of pIgA-R present in the control reaction mixture was recovered in the pellet, with the remainder found in the supernatant. The pIgA-R recovered in the pellet consists predominantly of the 90-kDa fragment [which is released into the sealed lumen of the target PM (3) and is therefore pelletable], and low levels of the uncleaved 120-kDa form. The $\approx 20\%$ of 120-kDa pIgA-R recovered in the pellet is higher than the $\approx 10\%$ that pellets in the absence of target PM (Fig. 3A, untreated bars) and might be due to pIgA-R present in TCVs bound to the PM but not yet fused.

Different results were obtained when a reaction mixture containing TAP-depleted cytosol was incubated at 37°C for 60 min and then subjected to centrifugation. As shown in Fig. 4B (lanes 3 and 4), the majority of pIgA-R remained in the supernatant (the $\approx 10\%$ of pIgA-R found in the pellet is analogous to the background level seen in Fig. 3A, untreated bars). All of the pIgA-R was in the 120-kDa form. These results suggest that TAP is required for binding of TCVs to the target PM or, alternatively, that the centrifugation conditions are too stringent and dissociate bound TCVs from the target PM if fusion is prevented. To distinguish between these possibilities, we examined the distribution of pIgA-R when an ATP-depleted reaction mixture was centrifuged (16). As shown in Fig. 4B (lanes 5 and 6), the distribution of pIgA-R was $\approx 50\%$ in the pellet and $\approx 50\%$ in the supernatant, indicating that TCVs associate with the target PM in the absence of fusion. The pIgA-R recovered in the pellet is in the 120-kDa form. The fact that only $\approx 40\%$ ($\approx 50\%$ minus $\approx 10\%$ for background) of pIgA-R was associated with the target PM in the absence of ATP (lane 6) but $\approx 60\%$ of TCVs fuse with the target PM in the presence of ATP (lane 2) might be due to a limiting number

of binding sites on the target PM, suggesting that in the course of a normal reaction, the same PM sites are used for fusion of multiple TCVs.

Molecular Analysis of TAP. The sequence of full-length TAP cDNA (3860 nucleotides) reveals an open reading frame (ORF) of 959 amino acids, 96 nucleotides of 5' noncoding sequence, and a 3' untranslated sequence of 884 nucleotides, including a termination codon (nucleotides 2878–80, triple asterisks), a polyadenylation signal (nucleotides 3721–3726, boldface), and the beginning of the poly(A) tail (nucleotide 2748) (Fig. 5). The sequences of five TAP tryptic peptides obtained by microsequencing are present within the cDNA sequence (boxed residues), indicating that the ORF encodes rat liver TAP.

There are two in-frame ATGs (nucleotides 1–3 and 22–24, marked with single asterisks). The context of the first ATG does not conform to the consensus sequence for eukaryotic translation initiation (17) except for the conserved purine at position -3. The second ATG conforms perfectly to the translation start consensus sequence.

The predicted secondary structure of TAP includes (i) an N-terminal region (amino acids 1–650); (ii) an internal α -helical region (amino acids 650–930) containing several coiled-coil domains; and (iii) a C-terminal acidic region (amino acids 931–959). The N-terminal region contains two proline-rich regions at positions 357–363 and 597–604 (double asterisks). The N-terminal 70-amino acid region is basic, with a calculated pI of 10.22; the C terminus, with a calculated pI of 3.07, is acidic, suggesting that TAP might form a dipole.

The α -helical region contains three domains with strong coiled-coil-forming potential (I, amino acids 650–709; III, amino acids 783–828; IV, amino acids 843–930; shaded letters) as defined by the COILS2 program (18). Another region ($\approx 80\%$ probability of forming a coiled-coil structure) was detected between amino acids 728 and 766 (region II). Helix-breaking prolines and glycines are found flanking each of the putative coiled-coil regions. Electron microscopic analysis (data not shown) indicates that TAP is superficially similar to myosin in that two TAP polypeptides, each composed of a globular (≈ 9 nm) head and an elongated (≈ 45 nm) tail, form a homodimer by parallel association of the tails. The coiled-coil region of TAP shows $\approx 40\%$ similarity and $\approx 20\%$ identity with other coiled-coil-containing proteins such as myosins, tropomyosins, kinesins, CLIP-170, golgin p160, giantin, and tpr gene product (19–21).

Using the BLAST program we found the strongest homology between TAP and a human cDNA encoding a 99-amino acid ORF with a sequence 92% identical to the TAP sequence (amino acids 605–703 of TAP). A weaker homology was found to Uso1p, a yeast protein involved in ER to Golgi traffic. Uso1p is a hydrophilic protein of 1790 amino acids with a 1010-amino acid coiled-coil region (11). Using BESTFIT (of Genetics Computer Group package) and BLAST programs, we found 42% identity (65% similarity) between amino acids 21–85 of TAP and 18–84 of Uso1p (Fig. 5B, boxed residues) and 33% identity (53% similarity) between amino acids 98–259 of TAP and 118–277 of Uso1p. Within this last region there is a stretch of high homology (61% identity, 77% similarity) between amino acids 201–252 of TAP and 220–271 of Uso1p (Fig. 5B, boxed amino acids). The C-terminal homology includes the acidic region, which has 85% similarity between amino acids 932–954 of TAP and 1767–1788 of Uso1p (Fig. 5C, acidic amino acids in boldface) and the region that immediately precedes it with 43% identity over 37 amino acids (amino acids 898–934) (Fig. 5C, boxed amino acids). Interestingly, the sequence immediately preceding the start of the acidic domain, SKLKDLG, is 100% identical in both proteins (double underlined amino acids). The overall homology (28.5% identity between amino acids 1–644 of TAP and 1–760 of Uso1p and 28.65% identity between the coiled-coil domains) of both proteins is relatively low.




FIG. 4. TAP is required for targeting/binding of TCVs to the target apical PM. (A) Reaction mixtures containing untreated cytosol (lane 1), TAP-depleted cytosol (lane 2), or ATP-depleting system (lane 3) were incubated at 37°C for 60 min. Reactions were terminated and pIgA-R was immunoprecipitated and analyzed by SDS/PAGE and fluorography. (B) Analogous reaction mixtures were centrifuged and the pellet (P) and supernatant (S) fractions were immunoprecipitated with anti-pIgA-R antibodies. Immunoprecipitates were analyzed by SDS/PAGE and fluorography.

A

```

gggagagccggctcggggctaggccctcgggggcg -60
ggggcgctgctgttttcttggcggaggggctgtaagccggcggctgagcgcacgag -1
  atg aat ttc ctg cgc ggg ggt gta atg ggg ggt cag agt gcc gga ccc 45
  Met Asn Phe Leu Arg Gly Val Met Gly Gly Gln Ser Ala Gly Pro
  *
  16  cag cac aca gaa gct gag acg att cag aag ctg tgt gac cgc gta
  Gln His Thr Glu Ala Glu Thr Ile Gln Lys Leu Cys Asp Arg Val
  90
  gct tca tct act tta ctg gac gac cga aga aat gct gtc cgt gcc 135
  Ala Ser Ser Thr Leu Leu Asp Asp Arg Arg Asn Ala Val Arg Ala
  180
  ctt aag tca ctg tct aag aaa tac cgc ttg gaa gtg gga atc caa
  Leu Lys Ser Leu Ser Lys Lys Tyr Arg Leu Glu Val Gly Ile Gln
  225
  gcc atg gag cat ctt act cac gtc tta cag aca gat cgt tcy gat
  Ala Met Glu His Leu Ile His Val Leu Gln Thr Asp Arg Ser Asp
  270
  tct gaa ata ata ggc tat gct ttg gac aca ctc tat aat ata ata
  Ser Glu Ile Ile Ala Tyr Ala Leu Asp Thr Leu Tyr Asn Ile Ile
  315
  tcc aat gat gaa gag gaa gaa gta gaa aat tct aca aga cag
  Ser Asn Asp Glu Glu Glu Glu Val Glu Glu Asn Ser Thr Arg Gln
  360
  agt gag gat ttg gga agc caa ttt aca gaa att ttc att aag cag
  Ser Glu Asp Leu Gln Phe Thr Glu Ile Phe Ile Lys Gln
  405
  cca gaa aat gtc act ctg tta tct ttg ttg gag gag ttt gat
  Pro Glu Asn Val Thr Leu Leu Ser Leu Leu Gln Gln Phe Asn
  450
  ttc cac gtc cga tgg cct ggt gtt gta aga ctt ctg act tct tta
  Phe His Val Arg Trp Pro Gly Val Arg Leu Leu Thr Ser Leu Leu
  495
  aaa cag cta ggg cct cca gtc cag caa atc atc cta gtc agc ccc
  Lys Gln Leu Pro Pro Glu Gln Ile Ile Leu Val Ser Pro
  540
  atg ggt gtt tca aaa tta atg gac ttg ctg gca gat tcc agg gaa
  Met Gly Val Ser Lys Leu Met Asp Leu Leu Ala Asp Ser Arg Glu
  585
  att ata cgt aat gat ggc gtc tta cta ctg cag gca tta aca agy
  Ile Ile Arg Asn Asp Gly Val Leu Leu Leu Gln Ala Leu Thr Arg
  630
  agc aac gga ggc act cag aaa att gtt gct ttt gaa aat gct tct
  Ser Asn Gly Ala Ile Gln Lys Ile Val Ala Phe Glu Asn Ala Phe
  675
  gag aga cta ctg gac att att aca gag gag ggg aac agc gat gga
  Glu Arg Leu Leu Asp Ile Ile Thr Glu Glu Gly Asn Ser Asp Gly
  720
  ggt ata gta gta gaa gat ggt ttg att ttg ctc caa aat ttg tta
  Gly Ile Val Val Glu Asp Cys Leu Ile Leu Leu Gln Asn Leu Leu
  765
  aaa aac aac aat tcc aat caa aat ttt ttt aaa gaa ggc tct tat
  Lys Asn Asn Asn Ser Asn Gln Asn Phe Phe Lys Glu Gly Ser Tyr
  810
  att caa cgt atg aaa cgt ttg ttt gaa gtt gga gat gaa aat cct
  Ile Gln Arg Met Lys Ala Trp Phe Glu Val Gly Asp Glu Asn Pro
  855
  ggt tgg tca gca cag aaa gtc acc aat ctt cat tta atg ctc cag
  Gly Trp Ser Ala Gln Lys Val Thr Asn Leu His Leu Met Leu Gln
  900
  ctt gtc cgg gta ctg gtc tct ccc acc aac cct ccc ggt gct acc
  Leu Val Arg Val Leu Val Ser Pro Thr Asn Pro Pro Gly Ala Thr
  945
  agt agc tgc cag aag gcc atg ttc cag tgt ggg tta cta caa cag
  Ser Ser Cys Gln Lys Ala Met Phe Gln Cys Gly Leu Leu Gln Gln
  990
  ctt tgc act act ctg atg gct acc gga att cct gct gat atc ctg
  Lys Cys Thr Ile Leu Met Ala Thr Gly Ile Pro Ala Asp Ile Leu
  1035
  act gag acc ata aat act gta tca gaa gtt att cga ggc tgc caa
  Thr Glu Thr Ile Asn Thr Val Ser Glu Val Ile Arg Gly Cys Gln
  1080
  gta aat caa gac tac ttt gct tct gta aat ggc cct tca aat ccc
  Val Asn Gln Asp Tyr Phe Ala Ser Val Asn Ala Pro Ser Asn Pro
  **
  1125
  cca cga cgc gca act gtt gtc ctc atc tcc atg gtc aac gag
  Pro Arg Pro Ala Ile Val Leu Leu Met Ser Met Val Asn Glu
  **
  1170
  agg cag cca ttt gta ctg gtc gcc gtc ctc tac tgt ttc cag
  Arg Gln Pro Phe Val Leu Arg Cys Ala Val Leu Tyr Cys Phe Gln
  1215
  tgc ttc ctc tat aaa acg gag aaa gga caa gga gat att gty gcc
  Cys Phe Leu Tyr Lys Asn Glu Lys Gly Gln Gly Glu Ile Val Ala
  1260
  act ctg cta cct tcc act att gac gca aca ggt aac tcy gtc tca
  Thr Leu Leu Pro Ser Thr Ile Asp Ala Thr Gly Asn Ser Val Ser
  1305
  gct ggc cag ctg ctc gtc gga ggt ttg ttt tcc aca gac tcc ctc
  Ala Gly Gln Leu Leu Cys Gly Gly Leu Phe Ser Thr Asp Ser Leu
  1350
  tca aac tgg tyt gct gcc gty gcc ctc gcc cat gca ctg caa ggy
  Ser Asn Trp Cys Ala Ala Val Ala Leu Ala His Ala Leu Gln Gly
  1395
  aac gcc acc cag aag gag cag ctg ctc agy gtt cag ctg gcc acc
  Asn Ala Thr Gln Lys Glu Gln Leu Arg Val Gln Leu Ala Thr
  1440
  agc atc gcc aac ccc cca gty tcy ctc ttg cag cag tgc acc aac
  Ser Ile Gly Asn Pro Pro Val Ser Leu Leu Gln Gln Cys Thr Asn
  1485
  att ctg tcc cag gga agc aag ata cag aga gtc ggt ttg ttg
  Ile Leu Ser Gln Gly Ser Lys Ile Gln Thr Arg Val Gly Leu Leu
  1530
  atg ttg ctt gtc acc tgg tta agc aac tgt ccg att gct gta aca
  Met Leu Leu Cys Thr Trp Leu Ser Asn Cys Pro Ile Ala Val Thr
  1575
  cac ttt ctt cac aac tca gcc aat gtt cca ttt ctt aca gga cag
  His Phe Leu His Asn Ser Ala Asn Val Pro Phe Leu Thr Gly Gln
  1620
  att gca gaa aat ctc gga gaa gaa gag cag ttg gtc caa ggc tta
  Ile Ala Glu Asn Leu Gly Glu Glu Leu Gln Leu Val Gln Gly Leu
  1665
  tgt gcc ctt ctt ttg ggc att tca att tat ttc aac gac aac tca
  Cys Ala Leu Leu Glu Gly Ile Ser Ile Tyr Phe Asn Asp Asn Ser
  1710
  cta gaa aac tac acg aaa gag aca cta aag caa cta ata gag aag
  Leu Glu Asn Tyr Thr Lys Glu Lys Leu Lys Gln Leu Ile Glu Lys
  1755
  agg att ggc aaa gag aat tac ata gag aaa ctt gga ttt att agc
  Arg Ile Gly Lys Glu Asn Tyr Ile Glu Lys Leu Gly Phe Ile Ser
  1800
  aag cat gag tta tat ccc aga gca tct cag aaa ccc cag cca aac
  Lys His Glu Leu Tyr Pro Arg Ala Ser Gln Lys Pro Gln Pro Asn
  *
  1845
  ttt ccg agt cca gaa tac atg ata ttt gat cat gag ttt aca aaa
  Phe Pro Ser Pro Glu Tyr Met Ile Phe Asp His Glu Phe Thr Lys
  **
  
```

B

```

TAP 1 MNEIRGVWQGSAGQPHTEETIQRLDRVASSTLLDDRRNVAVKRLSKS 50
USO1 1 MDITQGLT...QQPKIQSDV...ETITPLDRVNSSTLSDRSNAVLGKRAF 47
51 KYRLEVGIQMEHLHVLQTRSDSELIAYALDT...LNIISDEE... 97
48 RQVRESVIASGLKPLNLTKRVNDEDSVKALLETITLIFLIPRDGHDDLT 97
98 ...VEENSTROSEDLGSOFT...EIPF...KQFEN.VTLLL 128
98 RGLWISQSRLQNKYPSPLWKRQEVDQFSLWADALQSDSLHLHLV 147
129 SLLEEFDFHWKPPQVRLITSL...KOLAPPQOHLIUSVQVSKWMDLLA 176
148 ERMELINFHRLTYQLLEAWMATPKLARSALISL...PISLSTWSSLLD 195
177 DSREIRINDVQLLQALTRSNGLRIVAFENAPERLLIDITTEEGNSDGG 226
196 IMHEPIRDEAILLMAVNDSPH...KLVAFENIFERLFSITEEGGLRGS 24
227 IVVEEDLILLQNLNNNNSNFPFSSYIQKMFAPVQ...DENPWS 273
246 LVNDCLSLNNILKYFNSMPTFLF...GNLKAHLIHLSEPTSQDEVFPVN 295

```

C

```

TAP 896 .....LEVTDSKRQDILLVLLADQDKKILSKSLKRLGHP... 939
USO1 1725 KAENSKLEANKRSSEIDQLLVTLDEKAKRYSKKLQVEF... 1774
940 SGDQDDDDLDGDRDQDI 954
1775 .DDEENDEESSQVA 1788

```

FIG. 5. (Legend appears at the bottom of the opposite page.)

The amino acid sequence of TAP was found to be identical to the unpublished sequence of p115 (8), a protein involved in intra-Golgi fusion (9, 10), indicating that TAP/p115 is a general factor operational at multiple membrane fusions.

TAP/p115 and Uso1p are present in the cytoplasm and associated with intracellular membranes (9, 11, 15, 22). TAP was initially identified as a component of TCVs (15), but subsequently we found that TAP is also present on secretory vesicles derived from the TGN and within the Golgi complex (unpublished results). p115 is detected predominantly within the Golgi complex in bovine fibroblasts (9) but its ultrastructural localization is currently unknown. Likewise, the subcellular localization of Uso1p has not been defined but it is likely that Uso1p is present on vesicles operational between the ER and the Golgi complex.

Vesicle targeting and fusion are dependent on reversible and ordered interactions between membrane receptors and soluble cytosolic factors (23, 24). Specifically, proteins present in the vesicles [v-SNAREs; e.g., synaptobrevin (SNARE, SNAP receptor)] would interact with a complementary protein (a t-SNARE; e.g., syntaxin) on the target membrane and this association would form the site for recruitment of the "fusion machinery," a complex that includes NSF and SNAPs (7, 25, 26). Our data showing that ATP-depletion allows the docking of TCVs to the target apical PM supports the hypothesis that the NSF-SNAP complex assembles onto docked vesicles.

How do we superimpose the requirement for TAP/p115 onto the proposed targeting/fusion scheme? Targeting specificities might result from the interactions of v-SNAREs and t-SNAREs. However, vesicle docking prior to targeting might demand the creation of a network of stable interactions between the vesicular and target membranes, facilitating the specific binding of v-SNAREs to t-SNAREs. We propose that TAP/p115 acts as a vesicular "anchor" by interacting with the target membrane and holding the vesicular and target membranes in proximity. This suggestion is based on data from the neuronal field; synaptic vesicles appear normally docked at the target membrane even when v-SNAREs are cleaved by clostridial toxins (and thus unable to form a stable complex), suggesting that SNAREs are not required for association of vesicles with the target membrane and other molecules must perform this function (27). We propose that TAP/p115 may provide such an activity.

FIG. 5 (*On opposite page*). Sequence of TAP and homology alignments. (A) cDNA and protein sequence of rat liver TAP. Numbers on right correspond to nucleotide position and those on left correspond to amino acid position. Amino acid sequences of five peptides obtained from tryptic digestion of purified TAP are boxed. The two putative initiator methionines are marked with single asterisks. Stop codon is indicated by triple asterisks. Putative coiled-coil domains are in shaded letters. Proline-rich sequences are marked with double asterisks. Acidic domain is underlined. (B) Alignment of TAP and Uso1p N-terminal sequences. Homologous regions are boxed. (C) Alignment of TAP and Uso1p C-terminal sequences. Acidic domain is indicated by residues in boldface letters. Homologous region is boxed and a stretch of identity is double underlined.

We thank Dr. J. Rothman for advice and helpful insights. We are grateful to Drs. G. Banting and T. Dawson for their generous gifts of cDNA libraries. We acknowledge Dr. G. Waters for providing results prior to publication. We thank Drs. J. Schwarzbauer, D. Winkelman, and A. Lupas for scientific input. We acknowledge the assistance of the Princeton Sequencing Facility and Princeton Monoclonal Facility. This work was supported by grants from the National Institutes of Health and the National Science Foundation.

- Barroso, M. & Sztul, E. S. (1994) *J. Cell Biol.* **124**, 83–100.
- Apodaca, G., Katz, L. A. & Mostov, K. E. (1994) *J. Cell Biol.* **125**, 67–86.
- Sztul, E., Colombo, M., Stahl, P. & Samanta, R. (1993) *J. Biol. Chem.* **268**, 1876–1885.
- Sztul, E. S., Howell, K. E. & Palade, G. E. (1985) *J. Cell Biol.* **100**, 1248–1254.
- Musil, L. S. & Baenziger, J. U. (1987) *J. Cell Biol.* **104**, 1725–1733.
- Musil, L. S. & Baenziger, J. U. (1988) *J. Biol. Chem.* **263**, 15799–15808.
- Clary, D. O., Griff, I. C. & Rothman, J. E. (1990) *Cell* **61**, 709–721.
- Sapperstein, S. K., Walter, D. M., Grosvenor, A. R., Heuser, J. E. & Waters, M. G. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 522–526.
- Waters, M. G., Clary, D. O. & Rothman, J. E. (1992) *J. Cell Biol.* **118**, 1015–1026.
- Elazar, Z., Orci, L., Ostermann, J., Amherdt, M., Tanigawa, G. & Rothman, J. E. (1994) *J. Cell Biol.* **124**, 415–424.
- Nakajima, H., Hirata, A., Ogawa, Y., Yonehara, T., Yoda, K. & Yamasaki, M. (1991) *J. Cell Biol.* **113**, 245–260.
- Sztul, E. S., Howell, K. E. & Palade, G. E. (1983) *J. Cell Biol.* **97**, 1582–1591.
- Harlow, E. & Lane, D. (1988) *Antibodies: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- Sambrook, J., Maniatis, T. & Fritsch, E. F. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- Sztul, E., Kaplin, A., Saucan, L. & Palade, G. (1991) *Cell* **64**, 81–89.
- Wattenberg, B. W., Balch, W. E. & Rothman, J. E. (1986) *J. Biol. Chem.* **261**, 2202–2207.
- Kozak, M. (1989) *J. Cell Biol.* **108**, 229–241.
- Lupas, A., Van Dyke, M. & Stock, J. (1991) *Science* **252**, 1162–1164.
- Espreafico, E. M., Cheney, R. E., Matteoli, M., Nascimento, A. A. C., De Camilli, P. V., Larson, R. E. & Mooseker, M. S. (1992) *J. Cell Biol.* **119**, 1541–1557.
- Warrick, H. M., De Lozanne, A., Leinwand, L. A. & Spudich, J. A. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 9433–9437.
- Pierre, P., Scheel, J., Rickard, J. E. & Kreis, T. E. (1992) *Cell* **70**, 887–900.
- Gow, A., Nelson, D., Rahim, S. & Sztul, E. (1993) *Eur. J. Cell Biol.* **61**, 184–188.
- Rothman, J. E. & Warren, G. (1994) *Curr. Biol.* **4**, 220–232.
- Ferro-Novick, S. & Jahn, R. (1994) *Nature (London)* **370**, 191–193.
- Söllner, T., Whiteheart, S. W., Brunner, M., Erdjument-Bromage, H., Geromanos, S., Tempst, P. & Rothman, J. E. (1993) *Nature (London)* **362**, 318–324.
- Whiteheart, S. W., Rossmagel, K., Buhrow, S. A., Brunner, M., Jaenicke, R. & Rothman, J. E. (1994) *J. Cell Biol.* **126**, 945–954.
- Südhof, T. C., De Camilli, P., Niemann, H. & Jahn, R. (1993) *Cell* **75**, 1–4.